BDSI - BioDelivery Sciences International, Inc.
| Previous Close | 4.4900 |
| Open | 4.5200 |
| Bid | 4.63 x 2900 |
| Ask | 4.70 x 3200 |
| Day's Range | 4.5100 - 4.7500 |
| 52 Week Range | 1.7000 - 4.7500 |
| Volume | 762,636 |
| Avg. Volume | 616,001 |
| Market Cap | 327.852M |
| Beta (3Y Monthly) | -0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Mar 13, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.20 |
- Zacks•2 days ago
Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock
Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.
- Zacks•2 days ago
Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.
- Zacks•3 days ago
Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
- Zacks•5 days ago
5 Tiny Biotech Stocks With Superb Growth Potential
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
- Zacks•7 days ago
Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
- Investopedia•12 days ago
Penny Stocks to Watch for February 2019
Momentum of the Russell 2000 implies more realistic valuations and higher prices for these high-quality penny stocks.
- Zacks•14 days ago
What's in the Cards for Glaxo (GSK) This Earnings Season?
Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.
- GlobeNewswire•14 days ago
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
More Than 115 Million Lives Now Have Preferred Access To BELBUCA In The U.S. RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that a leading national managed care organization has moved BELBUCA into preferred status across all its commercial formularies from its previous position of not-covered effective February 1, 2019. This significant improvement in access for more than 7 million covered lives brings the total of Americans with preferred access for BELBUCA to more than 115 million.
- Zacks•20 days ago
Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
- Zacks•26 days ago
BioDelivery Sciences International (BDSI) is a Great Momentum Stock: Should You Buy?
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks•last month
Zacks.com featured highlights include: Rent-A-Center, BioDelivery , Seabridge, Marchex and DSP
Zacks.com featured highlights include: Rent-A-Center, BioDelivery , Seabridge, Marchex and DSP
- GlobeNewswire•last month
BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
RALEIGH, N.C., Jan. 15, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
- Zacks•last month
5 Breakout Stocks Offering Impressive Returns
The logic behind this kind of stock selection is to determine which stocks are trading within a narrow band.
- American City Business Journals•last month
From Iqvia to Red Hat: These execs raked in millions from stock sales in 2018
From Iqvia to Red Hat to Xerium Technologies, executives and investors at top Triangle firms raked in millions by selling shares in 2018, U.S. Securities and Exchange Commission filings show.
- Simply Wall St.•2 months ago
Should You Be Worried About Insider Transactions At BioDelivery Sciences International, Inc. (NASDAQ:BDSI)?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
- Insider Monkey•2 months ago
BioDelivery Sciences International, Inc. (BDSI): Are Hedge Funds Right About This Stock?
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
- GlobeNewswire•2 months ago
Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
Antares Pharma, Inc. (ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors. Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. (CERC), a biopharmaceutical company focused on neurological and pediatric disorders. He is also Chairman of the Board at BioDelivery Sciences (BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine.
- Zacks•2 months ago
BioDelivery (BDSI) Down 1.6% Since Last Earnings Report: Can It Rebound?
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BDSI earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 BioDelivery Sciences International Inc Earnings Call
- Zacks•3 months ago
BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q3. Sales were almost in line with the consensus mark.
- Zacks•3 months ago
BioDelivery Sciences International (BDSI) Reports Q3 Loss, Misses Revenue Estimates
BioDelivery (BDSI) delivered earnings and revenue surprises of 28.57% and -0.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
